Showing results (381-390 of 502) with videos related to
Sort By:
Pageof 51
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2015
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung CancerNathan R Foster, Lindsay A Renfro, Steven E Schild, et al.Sexually Transmitted Infections|August 7, 2003
Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri LankaF M Cowan, R S French, P Mayaud, et al.Cancer Medicine|August 30, 2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trialLaurie E Steffen McLouth, Fengmin Zhao, Taofeek K Owonikoko, et al.Cancer|August 19, 2018
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapyRobert H Press, Chao Zhang, Richard J Cassidy, et al.Nature Communications|February 27, 2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialJuliann Chmielecki, Tony Mok, Yi-Long Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2018
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian SubsetByoung Chul Cho, Busayamas Chewaskulyong, Ki Hyeong Lee, et al.JAMA Oncology|March 17, 2022
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)Kenneth L Kehl, David Zahrieh, Ping Yang, et al.Immunotherapy|April 21, 2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)Jacob M Sands, Sumithra J Mandrekar, David Kozono, et al.The Lancet. Oncology|December 3, 2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trialSuresh S Ramalingam, Pasi A Jänne, Tony Mok, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2020
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed PhenotypeTaofeek K Owonikoko, Bhakti Dwivedi, Zhengjia Chen, et al.Pageof 51